The estimated Net Worth of Regina E Groves is at least $1.44 Milion dollars as of 15 September 2021. Ms. Groves owns over 3,156 units of Atricure Inc stock worth over $435,619 and over the last 8 years she sold ATRC stock worth over $802,686. In addition, she makes $197,478 as Independent Director at Atricure Inc.
Sign up
Ms. Groves ATRC stock SEC Form 4 insiders trading
Regina has made over 6 trades of the Atricure Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 3,156 units of ATRC stock worth $235,848 on 15 September 2021.
The largest trade she's ever made was selling 6,313 units of Atricure Inc stock on 14 September 2020 worth over $264,073. On average, Regina trades about 845 units every 72 days since 2017. As of 15 September 2021 she still owns at least 16,194 units of Atricure Inc stock.
You can see the complete history of Ms. Groves stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Regina Groves biography
Regina E. Groves serves as Independent Director of the Company. Ms. Groves has served as one of our directors since March 2017. Ms. Groves currently serves as the Chief Operating Officer and a board member of Stimwave Technologies, Inc. a privately held medical device company. Ms. Groves was the Chief Executive Officer at REVA Medical, Inc., a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications from September 2015 to March 2019. Prior to joining REVA Medical, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, Inc., a leading global medical technology company. In this position, she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. Additionally, Ms. Groves successfully acquired and integrated companies, completed numerous clinical trials and launched novel products in the United States and worldwide. Prior to this, she was the Vice President of Quality and Regulatory for Medtronic’s Cardiac Rhythm Disease Management (CRDM) business from 2006 to 2008 and before that was Vice President and General Manager for Patient Management CRDM at Medtronic from 2002 to 2006. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration.
What is the salary of Regina Groves?
As the Independent Director of Atricure Inc, the total compensation of Regina Groves at Atricure Inc is $197,478. There are 8 executives at Atricure Inc getting paid more, with Michael Carrel having the highest compensation of $5,829,780.
How old is Regina Groves?
Regina Groves is 61, she's been the Independent Director of Atricure Inc since 2017. There are 4 older and 8 younger executives at Atricure Inc. The oldest executive at Atricure Inc is Sven Wehrwein, 69, who is the Independent Director.
What's Regina Groves's mailing address?
Regina's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.
Insiders trading at Atricure Inc
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie... oraz Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
What does Atricure Inc do?
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
What does Atricure Inc's logo look like?
Complete history of Ms. Groves stock trades at Atricure Inc i Fulgent Genetics Inc
Atricure Inc executives and stock owners
Atricure Inc executives and other stock owners filed with the SEC include:
-
Michael Carrel,
President, Chief Executive Officer, Director -
Douglas Seith,
Chief Operating Officer -
Salvatore Privitera,
Chief Technology Officer -
Justin Noznesky,
Senior Vice President, Marketing and Business Development -
Scott Drake,
Independent Chairman of the Board -
Sven Wehrwein,
Independent Director -
Mark Lanning,
Independent Director -
B. Kristine Johnson,
Independent Director -
Robert White,
Independent Director -
Regina Groves,
Independent Director -
Mark Collar,
Independent Director -
Karen Prange,
Independent Director -
Daniel Florin,
Independent Director -
Angela Wirick,
Chief Financial Officer -
Shlomo Nachman,
Director -
Karen P Robards,
Director -
Elizabeth D Krell,
Director -
Richard M Johnston,
Director -
Michael D Hooven,
Director -
Andrew L Lux,
V.P. & Chief Operating Officer -
Group I, Llc Murphy Michael...,
-
M. Andrew Wade,
CFO -
Tonya Austin,
Chief Human Resources Officer -
Deborah L Morley,
VP Clinical Affairs -
Lee R Wrubel,
Director -
Maureen Shaffer,
Vice President Marketing -
Jon A Sherman,
VP Product Development -
Elsa Chi Abruzzo,
VP; Regulatory&ClinicalAffairs -
Alan L Kaganov,
Director -
Richard S Walsh,
Vice President; Sales -
Management Group Viii L L C...,
-
Management Group Viii L L C...,
-
Stephen S Cambridge,
Vice President; Sales -
Management Group Viii L L C...,
-
Thomas J Etergino,
Vice President and CFO -
Norman R Weldon,
Director -
Patricia J Kennedy,
VP, GM, International -
James L Lucky,
VP; QA & Healthcare Compliance -
Management Group Viii L L C...,
-
David J Drachman,
President and CEO -
Richard Mcamden Partners St...,
-
Richard Mcamden Partners St...,
-
Donald C Harrison,
Director -
Group I, Llc Donoghue Danie...,
-
Stewart W Strong,
Vice President US Sales -
Management Group Viii L L C...,
-
Frederick Preiss,
Vice President; Operations -
Julie A Piton,
VP and CFO -
Deborah H Telman,
Director -
Karl S. Dahlquist,
Chief Legal Officer -
Vinayak Doraiswamy,
Chief Scientific Officer -
Maggie Yuen,
Director -
Deborah Lee Yount,
Chief Human Resources Officer